188812-95-5

Basic information

• Product Name: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID
• Synonyms: DL-3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID;3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID;RARECHEM AK HW 0006;3-AMINO-3-(3,5-DICHLOROPHENYL)PROPANOIC ACID
• CAS NO: 188812-95-5
• Molecular Formula: C₉H₉Cl₂NO₂
• Molecular Weight: 234.08
• Mol File: 188812-95-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 358.888 °C at 760 mmHg
• Flash Point: 170.85 °C
• Appearance: /
• Density: 1.448 g/cm³
• CAS DataBase Reference: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID(188812-95-5)
• EPA Substance Registry System: 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID(188812-95-5)

Safety Data

• Hazardous Substances Data: 188812-95-5(Hazardous Substances Data)

Usage

General Description

3-Amino-3-(3,5-Dichloro-Phenyl)-Propionic Acid is a chemical compound that belongs to the class of organic compounds known as phenylpropanoic acids. Its IUPAC name is 3-amino-3-(3,5-dichlorophenyl)propanoic acid. It is characterized by a phenylpropanoic acid moiety, which consists of a phenyl group substituted at the third position by a propanoic acid. 3-AMINO-3-(3,5-DICHLORO-PHENYL)-PROPIONIC ACID features an amino group, making it an amine, and a carboxylic acid group. Additionally, it contains two chlorines that are ortho to each other on a phenyl ring, which makes it a dichlorobenzene. Despite these properties, there's not much specific information available regarding its uses, side effects, or safety measures.

Upstream product

• 141-82-2 malonic acid 
• 10203-08-4 3,5-dichlorobenzaldehyde 

Downstream Products

• 406692-08-8 3-(2-tert-butoxycarbonylamino-acetylamino)-3-(3,5-dichloro-phenyl)-propionic acid methyl ester 

Relevant articles and documents

PYRROLOPYRAZINE DERIVATIVES AS ALPHA V INTEGRIN INHIBITORS

The disclosure relates to compounds of formula I: Formula I which inhibit αv-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.

CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv- containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Structure activity relationships of αv integrin antagonists for pulmonary fibrosis by variation in aryl substituents

Antagonism of αvβ6 is emerging as a potential treatment of idiopathic pulmonary fibrosis based on strong target validation. Starting from an αvβ3 antagonist lead and through simple variation in the nature and position of the aryl substituent, the discovery of compounds with improved αvβ6 activity is described. The compounds also have physicochemical properties commensurate with oral bioavailability and are high quality starting points for a drug discovery program. Compounds 33S and 43E1 are pan αv antagonists having ca. 100 nM potency against αvβ3, αvβ5, αvβ6, and αvβ8 in cell adhesion assays. Detailed structure activity relationships with these integrins are described which also reveal substituents providing partial selectivity (defined as at least a 0.7 log difference in pIC50 values between the integrins in question) for αvβ3 and αvβ5.